R

Ultragenyx Pharmaceutical
D

RARE

39.331
USD
0.42
(1.08%)
مغلق
حجم التداول
43,527
الربح لكل سهم
-5
العائد الربحي
-
P/E
-6
حجم السوق
3,693,167,803
أصول ذات صلة
B
BLUE
-0.15000
(-3.69%)
3.91000 USD
C
CRSP
0.520
(1.38%)
38.220 USD
E
EDIT
0.01500
(0.93%)
1.63000 USD
N
NTLA
0.20000
(2.32%)
8.83000 USD
S
SGMO
-0.01210
(-1.63%)
0.72800 USD
V
VYGR
0.10000
(2.82%)
3.64000 USD
المزيد
الأخبار المقالات

العنوان: Ultragenyx Pharmaceutical

القطاع: Healthcare
الصناعة: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.